Cite
HARVARD Citation
Aggarwal, C. et al. (2022). Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Journal for immunotherapy of cancer. 10 (4), p. . [Online].